Therapeutic Antibody‐Based Drugs in the Treatment of Human Inflammatory Disorders

Publisher:
In Tech
Publication Type:
Chapter
Citation:
"Immunotherapy - Myths, Reality, Ideas, Future", book edited by Krassimir Metodiev, ISBN 978-953-51-3106-9, Print ISBN 978-953-51-3105-2, 2017, pp. 223 - 270
Issue Date:
2017-04-26
Metrics:
Full metadata record
Files in This Item:
Filename Description Size
Sedger_LM_EtAl_InTechBookChapter_2017.pdfPublished version2.93 MB
Adobe PDF
Abstract. Inflammation causes debilitating human conditions and older treatments rely on global immunosuppression that non‐specifically alleviates symptoms. Currently, several monoclonal antibodies (mAbs) are available that specifically block pro‐inflammatory cytokines. These include mAbs specific to tumour necrosis factor (TNF), interleukin (IL)‐1β, IL‐6, IL‐17 and IL‐12/IL‐23. The chapter summarises the key elements in human inflammatory disease conditions, including various forms of arthritis, psoriasis, Crohn's disease and ulcerative colitis, plus pyrin‐associated inflammatory syndromes and periodic fevers, to explain the benefit of cytokine neutralisation through mAb‐type reagents. The chapter reviews the efficacy and safety of the current repertoire of anti‐cytokine/cytokine receptor mAbs. It also discusses the known side effects and adverse events that are sometimes associated with systemic blockade of cytokines in vivo, and concludes that the accumulating knowledge of treatment failures can reveal unappreciated aspects of cytokine biology and even new treatment opportunities. The chapter includes mention of the rapidly expanding cohort of biosimilar mAbs and the mAbs to IL‐4, IL‐5 and IL‐13 that are now emerging, in addition to the need for treatments for disorders that remain refractory to the current repertoire of anti‐cytokine mAbs and conventional treatments. Thus, here we summarise the current status of anti‐cytokine mAbs for human inflammatory diseases.
Please use this identifier to cite or link to this item: